Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma von Palumbo, Antonio, Chanan-Khan, Asher, Weisel, Katja, Nooka, Ajay K, Masszi, Tamas, Beksac, Meral, Spicka, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria V, Mark, Tomer M, Qi, Ming, Schecter, Jordan, Amin, Himal, Qin, Xiang, Deraedt, William, Ahmadi, Tahamtan, Spencer, Andrew, Sonneveld, Pieter

Volltext

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma von Dimopoulos, Meletios A, Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J, Usmani, Saad Z, Rabin, Neil, Orlowski, Robert Z, Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G, Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z, O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Volltext

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma von Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P, Weisel, Katja, Mace, Joseph R, Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M, Kobos, Rachel, Qi, Ming, Usmani, Saad Z

Volltext

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma von Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar

Volltext

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial von Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

Volltext

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond von van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.

Volltext

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy von Oostendorp, Marlies, Lammerts van Bueren, Jeroen J., Doshi, Parul, Khan, Imran, Ahmadi, Tahamtan, Parren, Paul W.H.I., van Solinge, Wouter W., De Vooght, Karen M.K.

Volltext

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma von Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A. Kate, Guckert, Mary E., de Boer, Carla, Khokhar, Nushmia Z., Yeh, Howard, Clemens, Pamela L., Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G.

Volltext

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma von Casneuf, Tineke, Xu, Xu Steven, Adams, Homer C., Axel, Amy E., Chiu, Christopher, Khan, Imran, Ahmadi, Tahamtan, Yan, Xiaoyu, Lonial, Sagar, Plesner, Torben, Lokhorst, Henk M., van de Donk, Niels W.C.J., Clemens, Pamela L., Sasser, A. Kate

Volltext

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation von Muik, Alexander, Altintas, Isil, Gieseke, Friederike, Schoedel, Kristina B, Burm, Saskia M, Toker, Aras, Salcedo, Theodora W., Verzijl, Dennis, Eisel, David, Grunwitz, Christian, Kranz, Lena M, Vormehr, Mathias, Satijn, David P.E., Diken, Mustafa, Kreiter, Sebastian, Sasser, Kate, Ahmadi, Tahamtan, Türeci, Özlem, Breij, Esther C.W., Jure-Kunkel, Maria, Sahin, Ugur

Volltext

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity von Muik, Alexander, Adams III, Homer C, Gieseke, Friederike, Altintas, Isil, Schoedel, Kristina B, Blum, Jordan M, Sänger, Bianca, Burm, Saskia M, Stanganello, Eliana, Verzijl, Dennis, Spires, Vanessa M, Vascotto, Fulvia, Toker, Aras, Quinkhardt, Juliane, Fereshteh, Mark, Diken, Mustafa, Satijn, David P E, Kreiter, Sebastian, Ahmadi, Tahamtan, Breij, Esther C W, Türeci, Özlem, Sasser, Kate, Sahin, Ugur, Jure-Kunkel, Maria

Volltext

813 Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro von Imle, Andrea, Altintas, Isil, Nuermberger, Kristina, Blum, Jordan, Krause, Anna-Lena, Toker, Aras, Daszkiewicz, Lidia, Muik, Alexander, Gieseke, Friederike, Ahmadi, Tahamtan, Fellermeier-Kopf, Sina, Kemper, Kristel, Tuereci, Oezlem, Breij, Esther, Sahin, Ugur

Volltext

1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation von Pilones, Karsten, Sette, Angelica, Nuermberger, Kristina, Luijten, Monique, Köhne, Maren, Wolthoorn, Jasja, Muik, Alexander, Fellermeier-Kopf, Sina, Ahmadi, Tahamtan, Tuereci, Oezlem, Sahin, Ugur, Jure-Kunkel, Maria, Adams, Homer

Volltext

493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors von Johnson, Melissa, Lopez, Juanita, LoRusso, Patricia, Bauman, Jessica, Haggstrom, Daniel, Lagkadinou, Eleni, Bajaj, Gaurav, Türeci, Özlem, Adams, Homer, Şahin, Uğur, Fu, Yali, Ahmadi, Tahamtan, Rohrberg, Kristoffer

Volltext

786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data von Bajaj, Gaurav, Nazari, Fereshteh, Presler, Marc, Thalhauser, Craig, Forssmann, Ulf, Jure-Kunkel, Maria, Muik, Alexander, Lagkadinou, Eleni, Tureci, Özlem, Sahin, Ugur, Ahmadi, Tahamtan, Gupta, Manish

Volltext

CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-b... von Ahmadi, Tahamtan, Flies, Amanda, Efebera, Yvonne, Sherr, David H

Volltext

STAT3 is constitutively activated in Hodgkin cell lines von Kube, Dieter, Holtick, Udo, Vockerodt, Martina, Ahmadi, Tahamtan, Haier, Birgit, Behrmann, Iris, Heinrich, Peter C., Diehl, Volker, Tesch, Hans

Volltext

516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial von Aix, Santiago Ponce, Calvo, Emiliano, Moreno, Victor, Garralda, Elena, Cervantes, Andrés, Ramalingam, Suresh, Pérez, José Trigo, LoRusso, Patricia, Furqan, Muhammad, Cho, Daniel, Muik, Alexander, Lagkadinou, Eleni, Türeci, Özlem, Couto, Suzana, Pencheva, Nora, Forssmann, Ulf, Şahin, Uğur, Ahmadi, Tahamtan, Higgs, Brandon, Jure-Kunkel, Maria, Melero, Ignacio

Volltext

Analysis of Real‐World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD... von Usmani, Saad, Ahmadi, Tahamtan, Ng, Yvette, Lam, Annette, Desai, Avinash, Potluri, Ravi, Mehra, Maneesha

Volltext

561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation... von Muik, Alexander, Altintas, Isil, Kosoff, Rachelle, Gieseke, Friederike, Schödel, Kristina, Salcedo, Theodora, Burm, Saskia, Toker, Aras, Kranz, Lena, Vormehr, Mathias, Eisel, David, Fereshteh, Mark, Türeci, Özlem, Breij, Esther, Ahmadi, Tahamtan, Sahin, Ugur, Jure-Kunkel, Maria

Volltext